Press Releases

 – Seven Abstracts Selected for Poster Presentations – 

 WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 25, 2019-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that data on XERAVA will be featured in seven poster presentations at the Infectious Disease Society of America’s (IDSA) Infectious Disease Week (IDWeek) 2019, taking place October 2-6 in Washington, DC, at the Walter E. Washington Convention Center.

The details for the data presentations at IDWeek are as follows:

 XERAVA Poster Presentations 

 Poster title: Comparative Evaluation of ETEST® ERV* bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
Authors: Sauvonnet V, Fyfe C, Bouvier M, Fontaine S, Halimi D, Martelin R, Zambardi G
Date and time: Thursday, October 3 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 644
Session information: New Diagnostics

 Poster title: In vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
Authors: Basseres E, Miranda J, Gonzales-Luna A, Carlson T, Rashid T, Alam MJ, Garey K
Date and time: Thursday, October 3 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 688
Session information: Novel Antimicrobials and Approaches Against Resistant Bugs

 Poster title: In vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae
Authors: Jones C, Kline E, Nguyen MH, Clancy C, Shields R
Date and time: Thursday, October 3 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 710
Session information: Novel Antimicrobials and Approaches Against Resistant Bugs

 Poster title: Activity of Eravacycline Against Contemporary Gram-negative Clinical Isolates from New York City Hospitals
Authors: Iregui A, Khan Z, Landman D, Quale J
Date and time: Thursday, October 3 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 728
Session information: Novel Antimicrobials and Approaches Against Resistant Bugs

 Poster title: Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
Authors: Traczewski M, Beasley D, Harrington A, DesJarlais S, Garner O, Hastey C, Brookman R, Lockett Z, Chau J, Zimmer B
Date and time: Saturday, October 5 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 2132
Session information: Bacterial Diagnostics

 Poster title: Predictors of Empiric Carbapenem Therapy in Complicated Intra-Abdominal Infections in the US, 2013-2017: A Retrospective Cohort Study
Authors: Zilberberg M, Nathanson B, Lawrence K, Johnson C, Ditch K, Olesky M, Shorr A
Date and time: Saturday, October 5 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 2259
Session information: Clinical Outcomes of Infections with Resistant Organisms

 Poster title: An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal Infections Across US Hospitals
Authors: Lodise T, Izmailyan S, Olesky M, Lawrence K, Tsai L
Date and time: Saturday, October 5 from 12:15 p.m. – 1:30 p.m. ET 
Location: Hall B + C
Poster number: 2264
Session information: Clinical Outcomes of Infections with Resistant Organisms

 Additional Activities 

 
• Tetraphase will host a XERAVA exhibit booth (#1125) at IDWeek 2019 during exhibit hours: Thursday, October 4; from 11:45 a.m. – 6:00 p.m. ET; Friday, October 5 from 10:00 a.m. – 4:00 p.m. ET; and Saturday, October 6 from 10:00 a.m. – 2:00 p.m. ET. Tetraphase Medical Affairs also will be present at booth #1125 during exhibit hours.
 

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). Full abstracts can be found on the IDWeek website at http://www.idweek.org/.

 About XERAVA™ 
XERAVA (eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.

 Important Safety Information 

 To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  

Please see full prescribing information for XERAVA at www.XERAVA.com.

 About Tetraphase Pharmaceuticals, Inc. 
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA™ is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company’s pipeline also includes antibiotics TP-271 and TP-6076, which are Phase 2 ready, and TP-2846, which is in preclinical testing for acute myeloid leukemia. The Company intends to out license its pipeline candidates. Please visit www.tphase.com for more company information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190925005261/en/

Source: Tetraphase Pharmaceuticals, Inc.

 Media and Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com